The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - TerSera
Stock and Other Ownership Interests - TerSera
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
 
Richard D. Kim
Consulting or Advisory Role - Abbvie; AstraZeneca; Exelixis; Pfizer; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - AstraZeneca; Incyte
 
Nancy Joseph-Ridge
Employment - TerSera
Leadership - TerSera
Stock and Other Ownership Interests - TerSera
 
Jichang Du
No Relationships to Disclose
 
Janine North
Employment - TerSera
Leadership - TerSera
Stock and Other Ownership Interests - Abbvie; TerSera
Research Funding - TerSera
Patents, Royalties, Other Intellectual Property - Tersera
 
Cathy Warren
No Relationships to Disclose
 
Renuka V. Iyer
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Bayer; Eisai; Exelixis; Incyte; Ipsen; Lexicon; Merck; Novartis; QED therapeutics; Sandoz; Sun pharma; Tersera
Research Funding - Cleveland BioLabs (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - AstraZeneca; Genentech; Replimune